ImmuCell Corporation

NasdaqCM ICCC

ImmuCell Corporation EBITDA for the Trailing 12 Months (TTM) ending September 30, 2024: USD -575.53 M

ImmuCell Corporation EBITDA is USD -575.53 M for the Trailing 12 Months (TTM) ending September 30, 2024, a -17,853.24% change year over year. EBITDA means earnings before interest, taxes, depreciation, and amortization, which measures a company's operating performance by excluding non-operating expenses.
  • ImmuCell Corporation EBITDA for the Trailing 12 Months (TTM) ending September 30, 2023 was USD -3.21 M, a -239.33% change year over year.
  • ImmuCell Corporation EBITDA for the Trailing 12 Months (TTM) ending September 30, 2022 was USD 2.30 M, a 18.58% change year over year.
  • ImmuCell Corporation EBITDA for the Trailing 12 Months (TTM) ending September 30, 2021 was USD 1.94 M, a 44.85% change year over year.
  • ImmuCell Corporation EBITDA for the Trailing 12 Months (TTM) ending September 30, 2020 was USD 1.34 M, a 83.24% change year over year.
Key data
Date EBITDA Net Income EPS (Diluted) Shares (Diluted, Weighted)
Market news
Loading...
NasdaqCM: ICCC

ImmuCell Corporation

CEO Mr. Michael F. Brigham
IPO Date May 5, 1987
Location United States
Headquarters 56 Evergreen Drive
Employees 75
Sector Consumer Staples
Industries
Description

ImmuCell Corporation, an animal health company, develops, manufactures, and markets products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. It offers First Defense, an orally delivered scours preventive product for newborn dairy and beef calves; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. The company also provides California Mastitis Test that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, including a whey protein concentrate for the nutritional and feed supplement markets. In addition, it is involved in developing Re-Tain, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is headquartered in Portland, Maine.

Similar companies

MNOV

MediciNova, Inc.

USD 1.91

-4.02%

LIPO

Lipella Pharmaceuticals Inc.

USD 3.05

0.33%

RZLT

Rezolute, Inc.

USD 4.72

-0.63%

CVKD

Cadrenal Therapeutics, Inc. Common Stock

USD 15.99

0.00%

FENC

Fennec Pharmaceuticals Inc.

USD 5.64

-3.09%

ANEB

Anebulo Pharmaceuticals, Inc.

USD 1.60

5.96%

StockViz Staff

January 15, 2025

Any question? Send us an email